Inhibitory_effect_of_interleukin-4_on_the_in_vitro_growth_of_Ph1-positive_acute_lymphoblastic_leukemia_cells._We_investigated_the_effect_of_recombinant_human_interleukin-4_(rhIL-4)_on_the_in_vitro_growth_of_human_leukemia_cells_in_liquid_culture_and_3H-thymidine_incorporation_and_found_inhibitory_effects_on_the_growth_of_leukemic_cells_from_patients_with_Ph1-positive_acute_lymphoblastic_leukemia_(Ph1_ALL)_and_three_Ph1_ALL_cell_lines._However,_no_inhibitory_effects_were_seen_in_Ph1-positive_leukemic_cell_lines_derived_from_patients_with_chronic_myelogenous_leukemia_in_blast_crisis_and_various_types_of_Ph1-negative_leukemia_cells,_including_B-lineage_leukemia_cells._In_a_flow_cytometry_assay_of_IL-4_receptor_(IL-4R),_all_three_Ph1-positive_ALL_cell_lines_showed_the_presence_of_IL-4R_on_their_cell_surfaces,_and_the_IL-4-dependent_inhibition_on_the_growth_of_Ph1-positive_ALL_cells_was_abrogated_by_the_addition_of_either_monoclonal_or_polyclonal_antibodies_against_rhIL-4._Other_cytokines,_including_IL-2,_IL-3,_granulocyte-macrophage_colony-stimulating_factor_(CSF),_granulocyte-CSF,_and_IL-6,_showed_no_inhibitory_effects_on_the_growth_of_Ph1-ALL_cells,_but_tumor_necrosis_factor-alpha_(TNF-alpha)_and_interferon_(IFN)-alpha,_-beta,_and_-gamma_displayed_slight_inhibitory_effects_in_a_high_concentration._The_growth_inhibition_induced_by_rhIL-4_in_the_Ph1-positive_ALL_cells_was_not_abrogated_by_the_addition_of_antibodies_against_either_IFN-gamma_or_TNF-alpha._Furthermore,_these_cells_showed_no_significant_production_of_IFN-alpha,_-beta,_or_-gamma_or_TNF-alpha_after_exposure_to_rhIL-4,_thus_indicating_that_the_growth_inhibition_of_Ph1-positive_ALL_cells_by_rhIL-4_is_not_associated_with_IL-4-stimulating_production_of_these_factors._rhIL-4_caused_significant_inhibition_of_the_tyrosine_kinase_activity_in_these_Ph1-positive_ALL_cells,_similar_to_Herbimycin_A,_an_inhibitor_of_tyrosine_kinase_that_inhibited_the_tyrosine_kinase_activity_in_these_cells._Our_finding_suggests_that_the_clinical_evaluation_of_rhIL-4_may_offer_promising_therapeutic_possibilities_for_patients_with_Ph1-positive_ALL.